Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02592785
Recruitment Status : Completed
First Posted : October 30, 2015
Last Update Posted : April 18, 2018
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
Primary objectives of this study are to assess the safety and tolerability of BAY 1163877 in Japanese subjects with refractory, locally advanced or metastatic solid tumors and to characterize the PK of BAY 1163877

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BAY1163877 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : December 15, 2015
Actual Primary Completion Date : February 5, 2017
Actual Study Completion Date : December 6, 2017

Arm Intervention/treatment
Experimental: BAY1163877
Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
Drug: BAY1163877

Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.

Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.





Primary Outcome Measures :
  1. Number of an Treatment Emergent Adverse Event [ Time Frame: Up to 35 days after the last study drug administration ]
  2. Intensity of an Treatment Emergent Adverse Event graded using the NCI-CTCAE version 4.03 [ Time Frame: Up tp 35 days after the last study drug administration ]
  3. Maximum observed plasma concentration after single dose administration (Cmax) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  4. Cmax divided by dose (mg) per kg body weight (Cmax,norm) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  5. Cmax divided by dose (mg) (Cmax/D) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  6. Area under the plasma concentration vs time curve from zero to 12 hours p.a. after first-dose administration (AUC(0-12)) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose ]
  7. AUC(0-12) divided by dose (mg) per kg body weight (AUC(0-12) norm) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose ]
  8. AUC(0-12) divided by dose (mg) (AUC(0-12)/D) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose ]
  9. AUC from time zero to the last data point > LLOQ (lower limit of quantification) of BAY1163877 (AUC(0-tlast)) [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  10. AUC(0-tlast) divided by dose (mg) per kg body weight (AUC(0-tlast) norm) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  11. AUC(0-tlast) divided by dose (mg) (AUC(0-tlast)/D) of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  12. AUC of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  13. AUCnorm of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  14. AUC/D of BAY1163877 [ Time Frame: On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose ]
  15. Maximum Observed Drug Concentration in Plasma after multiple administrations (Cmax, md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  16. Cmax after multiple administrations divided by dose (mg) per kg body weight (Cmax,norm, md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  17. Cmax after multiple administrations divided by dose (mg) (Cmax/Dmd) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  18. AUC(0-12) after multiple administrations (AUC(0-12)md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  19. AUC(0-12) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-12)norm,md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  20. AUC(0-12) divided by dose (mg) after multiple administrations (AUC(0-12)/Dmd) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  21. AUC(0-tlast)after multiple administrations (AUC(0-tlast)md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  22. AUC(0-tlast) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-tlast) norm,md) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]
  23. AUC(0-tlast) after multiple administrations divided by dose (mg) (AUC(0-tlast)/Dmd) of BAY1163877 [ Time Frame: On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose ]

Secondary Outcome Measures :
  1. Tumor response evaluation based on RECIST 1.1 [ Time Frame: Screening, end of every second cycle (i.e., Cycle 2, 4, 6, 8,…) ]
  2. FGF23 levels [ Time Frame: Cycle 1 (Days 1 and 15) ]
    FGF 23: fibroblast growth factor 23

  3. Phosphate levels [ Time Frame: Cycle 1 (Days 1, 8, 15), Cycle 2 to 12 (Days 1, 8, 15), Cycle ≥13 (Days 1, 11), end of treatment ]
  4. FGFR1/2/3 mRNA expression in tumor tissue to evaluate of biomarker status [ Time Frame: At Screening visit ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Japanese males or female aged ≥ 20 years
  • Histologically or cytologically confirmed refractory, locally advanced or metastatic solid tumors who are not candidates for standard therapy at discretion of investigator
  • High FGFR expression levels based on archival or fresh tumor biopsy specimen analysis. Bladder cancer subjects with low overall FGFR expression levels can be included if activating FGFR3 mutations are confirmed.
  • Subjects must have at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
  • Life expectancy of at least 3 months
  • Recovery to National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v4.03) Grade < 2 level or recovery to baseline preceding the prior treatment from any previous drug / procedure-related toxicity (subjects with persistent alopecia, anemia, and/or hypothyroidism can be included)
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2
  • Adequate bone marrow, liver and renal function
  • Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN. Subjects being treated with anticoagulant, e.g. warfarin or heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists

Exclusion Criteria:

  • History or current condition of an uncontrolled cardiovascular disease including congestive heart failure New York Heart Association (NYHA) > Class 2, unstable angina (symptoms of angina at rest) or new-onset angina (within last 3 months) or myocardial infarction within past 6 months and cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted)
  • Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiography performed
  • Subjects with history and/or current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis). Calcium (Ca) x (time) phosphate (PO4) should be < 70 mg²/dL².
  • Current evidence of corneal disorder / keratopathy including but not limited to bullous / band keratopathy, corneal abrasion, inflammation / ulceration, keratoconjunctivitis etc. (to be confirmed by ophthalmologic examination). Pre-existing cataract is not an exclusion criterion.
  • Moderate or severe hepatic impairment (subjects with Child-Pugh score B or C cannot be included.)
  • Known human immunodeficiency virus (HIV) infection
  • Subjects with an active hepatitis B and/or C infection requiring treatment
  • Anticancer chemotherapy or immunotherapy during the study or within 5-half-lives of anticancer chemotherapy or immunotherapy before start of study treatment.
  • Systolic blood pressure ≤ 110 and pulse rate ≥ 100/min, or diastolic blood pressure ≤ 70 mmHg and pulse rate ≥ 100/min
  • Uncontrolled hypertension as indicated by a resting systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02592785


Locations
Layout table for location information
Japan
Kashiwa, Chiba, Japan, 277-8577
Koto-ku, Tokyo, Japan, 135-8550
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02592785    
Other Study ID Numbers: 16958
First Posted: October 30, 2015    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: April 2018